Research Centre for Pharmaceutical Care and Pharmaco-economics, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven. Onderwijs en Navorsing 2, Herestraat 49, 3000 Leuven, Belgium.
Int J Environ Res Public Health. 2010 Apr;7(4):1835-40. doi: 10.3390/ijerph7041835. Epub 2010 Apr 20.
An article published in this Journal argued that New Zealand does not apply a cost-effectiveness threshold because medicines are funded within a fixed budget and because cost-effectiveness is only one of nine criteria that inform decisions. This Comment has explained that, from a theoretical perspective, the cost-effectiveness threshold model is not inconsistent with these two arguments. The observed annual variation in incremental cost-effectiveness ratios in New Zealand may originate from yearly differences in new medicines that request reimbursement and in the budget size, and from the fact that decision makers take into account other decision criteria in addition to cost-effectiveness.
本刊发表的一篇文章认为，新西兰没有应用成本效益阈值，因为药品是在固定预算内资助的，并且成本效益只是九个决策标准之一。本评论解释了，从理论角度来看，成本效益阈值模型与这两个论点并不矛盾。新西兰增量成本效益比的年度变化可能源于每年需要报销的新药和预算规模的差异，以及决策者除了成本效益之外还考虑了其他决策标准。
